Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC

Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.

AI Summary: Federal regulators and two pharmacy benefit managers are reportedly making substantial progress toward resolving an FTC antitrust probe tied to insulin pricing and PBM practices. Negotiations aim to settle allegations without protracted litigation, potentially changing how PBMs operate and how insulin costs are managed for states and patients.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Hospitals push regulators to block expanded 340B claims reporting requirements / 2 months

CVS sues Tennessee over PBM‑pharmacy separation law / 4 days

One in three Americans cut expenses to afford healthcare / 2 months

AbbVie sues over Botox selection in Medicare price negotiations / 3 months

HHS drops 340B pilot following court rulings / 3 months

HHS scraps 340B rebate pilot following court rulls / 3 months

FTC settles insulin lawsuit forces Express Scripts policy changes / 3 months